Article | Published:

An essential role for the Zn2+ transporter ZIP7 in B cell development

Nature Immunologyvolume 20pages350361 (2019) | Download Citation


Despite the known importance of zinc for human immunity, molecular insights into its roles have remained limited. Here we report a novel autosomal recessive disease characterized by absent B cells, agammaglobulinemia and early onset infections in five unrelated families. The immunodeficiency results from hypomorphic mutations of SLC39A7, which encodes the endoplasmic reticulum-to-cytoplasm zinc transporter ZIP7. Using CRISPR-Cas9 mutagenesis we have precisely modeled ZIP7 deficiency in mice. Homozygosity for a null allele caused embryonic death, but hypomorphic alleles reproduced the block in B cell development seen in patients. B cells from mutant mice exhibited a diminished concentration of cytoplasmic free zinc, increased phosphatase activity and decreased phosphorylation of signaling molecules downstream of the pre-B cell and B cell receptors. Our findings highlight a specific role for cytosolic Zn2+ in modulating B cell receptor signal strength and positive selection.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Data availability

RNA-sequencing data generated for this study (Fig. 5 and Supplementary Figs. 4 and 5) have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE108178. Other data that support the findings of this study (including raw data supporting Fig. 1 and Supplementary Fig. 1) are available from the corresponding authors upon reasonable request.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the SRC family of protein-tyrosine kinases. Nature 361, 226–233 (1993).

  2. 2.

    Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279–290 (1993).

  3. 3.

    Aw, A. & Brown, J. R. Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies. Drugs Aging 34, 509–527 (2017).

  4. 4.

    Conley, M. E. Genetics of hypogammaglobulinemia: what do we really know? Curr. Opin. Immunol. 21, 466–471 (2009).

  5. 5.

    Durandy, A., Kracker, S. & Fischer, A. Primary antibody deficiencies. Nat. Rev. Immunol. 13, 519–533 (2013).

  6. 6.

    Conley, M. E. et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J. Exp. Med. 209, 463–470 (2012).

  7. 7.

    Feske, S. et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441, 179–185 (2006).

  8. 8.

    Li, F. Y. et al. Second messenger role for Mg2 + revealed by human T-cell immunodeficiency. Nature 475, 471–476 (2011).

  9. 9.

    Kambe, T., Hashimoto, A. & Fujimoto, S. Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cell. Mol. Life Sci. 71, 3281–3295 (2014).

  10. 10.

    Lichten, L. A. & Cousins, R. J. Mammalian zinc transporters: nutritional and physiologic regulation. Annu. Rev. Nutr. 29, 153–176 (2009).

  11. 11.

    Hojyo, S. et al. Zinc transporter SLC39A10/ZIP10 controls humoral immunity by modulating B-cell receptor signal strength. Proc. Natl Acad. Sci. USA 111, 11786–11791 (2014).

  12. 12.

    Taylor, K. M. et al. Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters. Biochem. J. 377(Pt 1), 131–139 (2004).

  13. 13.

    Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).

  14. 14.

    Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).

  15. 15.

    Zhang, T. et al. Crystal structures of a ZIP zinc transporter reveal a binuclear metal center in the transport pathway. Sci. Adv. 3, e1700344 (2017).

  16. 16.

    Vinkenborg, J. L. et al. Genetically encoded FRET sensors to monitor intracellular Zn2+ homeostasis. Nat. Methods 6, 737–740 (2009).

  17. 17.

    Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  18. 18.

    Hardy, R. R. et al. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173, 1213–1225 (1991).

  19. 19.

    Dengler, H. S. et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9, 1388–1398 (2008).

  20. 20.

    Tussiwand, R. et al. BAFF-R expression correlates with positive selection of immature B cells. Eur. J. Immunol. 42, 206–216 (2012).

  21. 21.

    Holl, T. M., Haynes, B. F. & Kelsoe, G. Stromal cell independent B cell development in vitro: generation and recovery of autoreactive clones. J. Immunol. Methods 354, 53–67 (2010).

  22. 22.

    Corfe, S. A., Gray, A. P. & Paige, C. J. Generation and characterization of stromal cell independent IL-7 dependent B cell lines. J. Immunol. Methods 325, 9–19 (2007).

  23. 23.

    Chabosseau, P. et al. Mitochondrial and ER-targeted eCALWY probes reveal high levels of free Zn2+. ACS. Chem. Biol. 9, 2111–2120 (2014).

  24. 24.

    Maares, M. et al. Characterization of Caco-2 cells stably expressing the protein-based zinc probe eCalwy-5 as a model system for investigating intestinal zinc transport. J. Trace Elem. Med. Biol. 49, 296–304 (2018).

  25. 25.

    Ohashi, W. et al. Zinc transporter SLC39A7/ZIP7 promotes intestinal epithelial self-renewal by resolving ER stress. PLoS Genet. 12, e1006349 (2016).

  26. 26.

    Bin, B. H. et al. Requirement of zinc transporter SLC39A7/ZIP7 for dermal development to fine-tune endoplasmic reticulum function by regulating protein disulfide isomerase. J. Invest. Dermatol. 137, 1682–1691 (2017).

  27. 27.

    Strasser, A. et al. Bcl-2 expression promotes B- but not T-lymphoid development in SCID mice. Nature 368, 457 (1994).

  28. 28.

    Reth, M. & Nielsen, P. Signaling circuits in early B-cell development. Adv. Immunol. 122, 129–175 (2014).

  29. 29.

    Levine, M. H. et al. A B-cell receptor-specific selection step governs immature to mature B cell differentiation. Proc. Natl Acad. Sci. USA 97, 2743–2748 (2000).

  30. 30.

    Phan, T. G. et al. B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J. Exp. Med. 197, 845–860 (2003).

  31. 31.

    Brautigan, D. L., Bornstein, P. & Gallis, B. Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn. J. Biol. Chem. 256, 6519–6522 (1981).

  32. 32.

    Haase, H. & Maret, W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp. Cell Res. 291, 289–298 (2003).

  33. 33.

    Plum, L. M. et al. PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation. Metallomics 6, 1277–1287 (2014).

  34. 34.

    Kury, S. et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat. Genet. 31, 239–240 (2002).

  35. 35.

    Fraker, P. J. & King, L. E. Reprogramming of the immune system during zinc deficiency. Annu. Rev. Nutr. 24, 277–298 (2004).

  36. 36.

    Woodruff, G. et al. The zinc iransporter SLC39A7 (ZIP7) is ssential for regulation of cytosolic zinc levels. Mol. Pharmacol. 94, 1092–1100 (2018).

  37. 37.

    Groth, C. et al. Protein trafficking abnormalities in Drosophila tissues with impaired activity of the ZIP7 zinc transporter Catsup. Development 140, 3018–3027 (2013).

  38. 38.

    Yan, G. et al. Slc39a7/zip7 plays a critical role in development and zinc homeostasis in zebrafish. PLoS ONE 7, e42939 (2012).

  39. 39.

    Taniguchi, M. et al. Essential role of the zinc transporter ZIP9/SLC39A9 in regulating the activations of Akt and Erk in B-cell receptor signaling pathway in DT40 cells. PLoS ONE 8, e58022 (2013).

  40. 40.

    Ubieta, K. et al. Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription. J. Exp. Med. 214, 2059–2071 (2017).

  41. 41.

    Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176–184 (2009).

  42. 42.

    Geiser, J. et al. Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica. PLoS ONE 8, e72543 (2013).

  43. 43.

    Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows–Wheeler transform. Bioinformatics 26, 589–595 (2010).

  44. 44.

    McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).

  45. 45.

    Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

  46. 46.

    Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171–181 (2014).

  47. 47.

    Sims, D. et al. CGAT: computational genomics analysis toolkit. Bioinformatics 30, 1290–1291 (2014).

  48. 48.

    Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357–360 (2015).

  49. 49.

    Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

  50. 50.

    Holl, T. M., Haynes, B. F. & Kelsoe, G. Stromal cell-independent B-cell development in vitro: generation and recovery of autoreactive clones. J Immunol Methods. 354, 53–67 (2010).

  51. 51.

    Hessels, A. M., Taylor, K. M. & Merkx, M. Monitoring cytosolic and ER Zn(2+) in stimulated breast cancer cells using genetically encoded FRET sensors. Metallomics 8, 211–217 (2016).

  52. 52.

    Padilla-Parra, S. et al. Quantitative FRET analysis by fast acquisition time domain FLIM at high spatial resolution in living cells. Biophys. J. 95, 2976–2988 (2008).

  53. 53.

    Merola, F. et al. Newly engineered cyan fluorescent proteins with enhanced performances for live cell FRET imaging. Biotechnol. J. 9, 180–191 (2014).

  54. 54.

    Markovich, D. Expression cloning and radiotracer uptakes in Xenopus laevis oocytes. Nat. Protoc. 3, 1975–1980 (2008).

  55. 55.

    Turk, E. et al. Membrane topology of the human Na+ /glucose cotransporter SGLT1. J. Biol. Chem. 271, 1925–1934 (1996).

  56. 56.

    Yoshida, H. et al. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881–891 (2001).

Download references


We thank colleagues in the Newcastle University Flow Cytometry and Bioimaging Facilities for assistance. We acknowledge N. Ashley, A. Mead, P. Sopp and C. Waugh for assistance with single cell experiments and flow cytometry, D. Biggs and C. Preece for generation of the mouse models and staff at the Oxford Functional Genomics Facility for animal care. We also thank the National Diagnostic Epidermolysis Bullosa Laboratory (St Thomas’ Hospital, London) and the NIHR Newcastle Biomedical Research Centre. We thank K. Taylor for helpful discussions. This work was supported by the Medical Research Council (MR/J0003042/1, MR/N00275X/1 and MR/L020149/1: DIVA) (C.A., R.J.C., E.F., J.C.C. and G.A.R.); the Sir Jules Thorn Trust (12/JTA) (S.H., D.S., T.S.D. and K.E.); the St Giles Foundation, the Rockefeller University, INSERM, Paris Descartes University, Howard Hughes Medical Institute, National Institutes of Health (5P01AI061093 and 5R01AI104857) and the French National Research Agency (ANR 14-CE15-0009-01) (B.B., S.J.d.J., J.-L.C. and M.E.C.); the Wellcome Trust (WT098424AIA; 090532/Z/09/Z and 207556/Z/17/Z) (P.C., G.A.R., J.R.C., S.P.-P., B.D. and S.H.); Cancer Research UK (C52690/A19270) (C.O. and J.R.C.); Diabetes UK (BDA11/0004210 and BDA/15/0005275) (P.C., G.A.R.); the Northern Counties Kidney Research Fund (14.06) (A.F. and A.W.); the National Health and Medical Research Council of Australia (C.S.M., S.G.T.) and the Ludwig Institute for Cancer Research (E.J.F. and J.C.C.). S.H. is a Wellcome Investigator and R.J.C. is a Principal Investigator of the MRC Human Immunology Unit.

Author information

Author notes

  1. These authors contributed equally: David J. Swan, Bertrand Boisson.


  1. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

    • Consuelo Anzilotti
    • , Mukta Deobagkar-Lele
    • , Xijin Xu
    • , Katherine R. Bull
    • , Eleanor Cawthorne
    • , Tanya L. Crockford
    • , B. Christoffer Lagerholm
    •  & Richard J. Cornall
  2. Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

    • David J. Swan
    • , Karin R. Engelhardt
    • , Rui Chen
    • , Tarana Singh Dang
    •  & Sophie Hambleton
  3. St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA

    • Bertrand Boisson
    • , Sarah J. de Jong
    • , Jean-Laurent Casanova
    •  & Mary Ellen Conley
  4. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163 Necker Hospital for Sick Children, Paris, France

    • Bertrand Boisson
    •  & Jean-Laurent Casanova
  5. Paris Descartes University, Imagine Institute, Paris, France

    • Bertrand Boisson
    •  & Jean-Laurent Casanova
  6. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

    • Catarina Oliveira
    • , Luis Alvarez
    • , J. Ross Chapman
    • , Benjamin Davies
    •  & Sergi Padilla-Parra
  7. Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College, London, UK

    • Pauline Chabosseau
    •  & Guy A. Rutter
  8. Bioimaging Unit, Newcastle University Medical School, Newcastle upon Tyne, UK

    • Rolando Berlinguer-Palmini
  9. MRC WIMM Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

    • Adam P. Cribbs
    •  & David Sims
  10. Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, UK

    • Amy Fearn
    • , Bert van den Berg
    •  & Andreas Werner
  11. Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK

    • Emma J. Fenech
    •  & John C. Christianson
  12. Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

    • Cindy S. Ma
    •  & Stuart G. Tangye
  13. St Vincent’s Clinical School, Faculty of Medicine, University of NSW, Darlinghurst, New South Wales, Australia

    • Cindy S. Ma
    •  & Stuart G. Tangye
  14. Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

    • Yaobo Xu
    •  & Mauro Santibanez Koref
  15. Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

    • Andrew J. Cant
    •  & Sophie Hambleton
  16. Pediatric Allergy and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA

    • Gary Kleiner
  17. Paediatric Immunology and Infectious Diseases, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland

    • T. Ronan Leahy
  18. Division of Immunology, Department of Pediatrics, University of Washington and Seattle Children’s Hospital, Seattle, WA, USA

    • M. Teresa de la Morena
  19. Department of Pediatrics, Division of Allergy, Immunology, and Blood and Bone Marrow Transplantation, University of California, San Francisco, CA, USA

    • Jennifer M. Puck
  20. UCSF Benioff Children’s Hospital, San Francisco, CA, USA

    • Jennifer M. Puck
  21. Midwest Immunology Clinic, Plymouth, MN, USA

    • Ralph S. Shapiro
  22. Department of Immunology, Erasmus University Medical Centre, Rotterdam, the Netherlands

    • Mirjam van der Burg
  23. St John’s Institute of Dermatology, King’s College London, London, UK

    • John A. McGrath
  24. Department of Biosciences, Durham University, Durham, UK

    • Stefan Przyborski
  25. Dynamic Structural Virology Group, Biocruces Health Research Institute, Barakaldo, Spain

    • Sergi Padilla-Parra
  26. Ikerbasque, Basque Foundation for Science, Bilbao, Spain

    • Sergi Padilla-Parra
  27. Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, Paris, France

    • Jean-Laurent Casanova
  28. Howard Hughes Medical Institute, New York, NY, USA

    • Jean-Laurent Casanova


  1. Search for Consuelo Anzilotti in:

  2. Search for David J. Swan in:

  3. Search for Bertrand Boisson in:

  4. Search for Mukta Deobagkar-Lele in:

  5. Search for Catarina Oliveira in:

  6. Search for Pauline Chabosseau in:

  7. Search for Karin R. Engelhardt in:

  8. Search for Xijin Xu in:

  9. Search for Rui Chen in:

  10. Search for Luis Alvarez in:

  11. Search for Rolando Berlinguer-Palmini in:

  12. Search for Katherine R. Bull in:

  13. Search for Eleanor Cawthorne in:

  14. Search for Adam P. Cribbs in:

  15. Search for Tanya L. Crockford in:

  16. Search for Tarana Singh Dang in:

  17. Search for Amy Fearn in:

  18. Search for Emma J. Fenech in:

  19. Search for Sarah J. de Jong in:

  20. Search for B. Christoffer Lagerholm in:

  21. Search for Cindy S. Ma in:

  22. Search for David Sims in:

  23. Search for Bert van den Berg in:

  24. Search for Yaobo Xu in:

  25. Search for Andrew J. Cant in:

  26. Search for Gary Kleiner in:

  27. Search for T. Ronan Leahy in:

  28. Search for M. Teresa de la Morena in:

  29. Search for Jennifer M. Puck in:

  30. Search for Ralph S. Shapiro in:

  31. Search for Mirjam van der Burg in:

  32. Search for J. Ross Chapman in:

  33. Search for John C. Christianson in:

  34. Search for Benjamin Davies in:

  35. Search for John A. McGrath in:

  36. Search for Stefan Przyborski in:

  37. Search for Mauro Santibanez Koref in:

  38. Search for Stuart G. Tangye in:

  39. Search for Andreas Werner in:

  40. Search for Guy A. Rutter in:

  41. Search for Sergi Padilla-Parra in:

  42. Search for Jean-Laurent Casanova in:

  43. Search for Richard J. Cornall in:

  44. Search for Mary Ellen Conley in:

  45. Search for Sophie Hambleton in:


C.A. designed and performed experiments, analyzed data and wrote the paper. R.J.C., M.E.C. and S.H. designed experiments, analyzed data and wrote the paper. D.J.S., B.B., T.S.D., M.D.-L., C.O., B.C.L., L.A., R.C., R.B.-P., P.C., M.v.d.B., B.D., A.W. and S.P.-P. designed and performed experiments and analyzed data. K.R.E., J.R.C., J.C.C., G.A.R., S.G.T., J.A.M., S.P. and J.-L.C. designed experiments and analyzed data. B.B., B.v.d.B., K.R.B., A.P.C., D.S., X.X., Y.X. and M.S.K. performed bioinformatic analysis. E.C., T.L.C., A.F., E.J.F., S.J.d.J. and C.S.M. performed experiments. A.J.C., G.K., T.R.L., M.T.d.l.M., J.M.P., R.S.S., M.E.C. and S.H. cared for patients and provided clinical data. All authors reviewed the manuscript

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Richard J. Cornall or Mary Ellen Conley or Sophie Hambleton.

Integrated supplementary information

  1. Supplementary Figure 1 Allele frequency and predicted severity and evolutionary conservation of mutated residues in SLC39A7.

    (a) Population frequency of putative pathogenic alleles of SLC39A7 (ZIP7) from the GNOMAD database13. (b) Combined Annotation Dependent Depletion (CADD)14 scores vs maximum mean allele frequencies of the SLC39A7 variants recorded in this study (red circles) and/or GNOMAD Database (blue circles for predicted null mutations (frameshift/stop/essential splicing), green circle (in-frame insertions and deletions) or gray circle (missense mutations)). None of the predicted null mutations or Inframe INDELS were found in the homozygous state. (c) Alignments of human ZIP7, mouse ZIP7 and Bordetella pertussis ZIP, generated as two pairwise alignments with human ZIP7 in BLAST-P, highlighting residues mutated in patients with agammaglobulinemia (missense, yellow; nonsense, pink) and predicted transmembrane segments (gray)15.

  2. Supplementary Figure 2 Mutant forms of ZIP7 are expressed but display reduced Zn transporter activity.

    (a) Fluorescence micrographs revealing expression of endogenous ZIP7 in primary dermal fibroblasts from healthy control or P1, stained with antibody against ZIP7 (red) and DAPI (blue). Scale bar, 20µm. (b) Impaired Zn2+ conductance of mutant forms of ZIP7 expressed in Xenopus oocytes, visualized by zinquin fluorescence. Left, fluorescence micrographs showing Zn2+-related zinquin signal and right, pairwise image analysis in ImageJ, as described in Methods. Images are representative of 4 independent experiments as exemplified in Fig 2h. (c) Western blot of detergent extracts of Xenopus oocytes injected in parallel with those visualized in (b), revealing expression of the recombinant ZIP7 proteins. Images are representative of 3 independent experiments. (d-e) Cytoplasmic Zn2+ concentration in HEK-293T cells stably expressing the genetically encoded cytoplasmic Zn2+ sensor eCALWY-4 and transfected with empty vector (EV), or vectors encoding WT, E363K (d) or P190A (e) ZIP7 proteins. Cytoplasmic Zn2+ concentration was calculated by comparing the steady state live cell fluorescence intensity with maximum and minimum signals obtained in the presence of TPEN and zinc pyrithione respectively, as described in Methods. Total number of cells analyzed was 80 (EV), 55 (WT), 26 (E363K) and 42 (P190A) across 2–4 experiments. Columns show means and bars the standard error. Comparisons were by one-way ANOVA with Bonferroni’s correction; * indicates p=0.0258 and ** p=0.0051.

  3. Supplementary Figure 3 Normal T cell development in ZIP7 P198A/P198A mice.

    (a-b) Representative flow cytometry of T cell subsets in the thymus (a) and spleen (b) of WT and ZIP7P198A/P198A (P198A-Hom) mice. Representative of 3 independent experiments (c-d) The percentage of B220+ B cells, naïve (CD62L+CD44-), activated (CD62L-CD44+) and memory (CD62L+CD44+) CD4+ and CD8+ T cells, NK cells (NK1.1+CD3-), neutrophils (B220-CD3-Ly6g+CD11b+Ly6c+) and monocytes (B220-CD3-Ly6c++F4/80-) within the leukocyte populations in wild-type (closed circles) and P198A-Hom (open circles) blood (c) and spleen (d). Representative of three separate experiments; circles represent individual mice, 5 WT and 5 P198A-Hom; bars means and 95% CI, and comparisons by two-way ANOVA with Bonferroni’s correction for multiple comparison; *p<0.0001. (e) The relative proportion of thymic or splenic CD4+ and CD8+ cells, in lethally irradiated mice reconstituted for 8 weeks with 70:30 mixtures of WT or P198A-Hom CD45.2+ and WT CD45.1+ BM. Filled columns show mean percentage CD45.2+ cells and data are representative of 3 experiments.

  4. Supplementary Figure 4 Transcriptomic analysis of WT and ZIP7-deficient B cells from Hardy fraction B.

    B220+CD43+CD24+BP1- pro-B cells were sorted flow-cytometrically and whole transcriptome analysis performed by RNAseq on 100 cell samples from WT and P198A-Hom mice. We identified genes whose transcription varied by at least two-fold between WT and P198A-Hom mice with Padj < 0.05 (see Methods). (a-c) Heatmaps show the relative expression level of the subset of these genes that are also differentially expressed during normal B cell development: (a) during the transition from Fractions A to B (reduced, purple and raised, blue), (b) during the transition from Fractions B to C (reduced, red and raised, green) and (c) between Fractions B and D (reduced, yellow and raised, orange), based on the ImmGen database ( In each heatmap, the far left column indicates the direction of change expected from ImmGen; each of the remaining columns represents one mouse and rows individual transcripts.

  5. Supplementary Figure 5 Transcriptomic analysis of WT and P198A-Hom B cells from Hardy fractions D and E.

    B220+CD43-IgM-IgD- late pre-B (FrD) and B220+CD43-IgM+IgD- immature B cells (FrE) were flow-sorted and whole transcriptome analysis performed by RNA-seq on 100 cell samples from WT and P198A-Hom mice. We identified genes whose transcription varied by at least two-fold between WT and P198A-Hom mice with Padj < 0.05 (see Methods) and filtered these against sets of genes that are also differentially expressed at the indicated stages of normal B cell development ( (a-b) Heatmaps showing the relative expression of the subset of genes that show differential expression between wild-type and P198A-Hom B cells in Hardy Fraction D and also (a) between Fractions C and D (reduced, yellow and raised, red) and (b) between Fractions D and E (reduced, green and raised, blue) of normal mice. (c) Heatmaps showing the relative expression level of the subset of genes that show differential expression between wild-type and P198A-Hom B cells in Hardy Fraction E and also between Fractions D and E (reduced, green and raised, blue) of normal mice. In each heatmap, the far left column indicates the direction of change expected from ImmGen; each of the remaining columns represents one mouse and rows individual transcripts.

  6. Supplementary Figure 6 The B cell developmental arrest caused by ZIP7 deficiency is not associated with endoplasmic reticulum (ER) stress and is not corrected by expression of the pro-survival factor BCL2.

    (a) RT-PCR assay for the ER-stress-associated shortened Xbp1-splice variant (Xbp1s). Results show RT-PCR of cDNA from WT (lanes 1–3) or P198A-Hom (lanes 4–6) flow-sorted B cells from FrD and FrE. The controls were tunicamycin treated (Tm) or untreated (Un) mouse embryonic fibroblasts (MEFs). Three mice were studied per genotype in the single experiment shown. (b-c) Representative flow cytometry analysis of B cell development and maturation in BM (b) and spleen (c) of WT and P198A-Hom mice, with and without co-expression of a Bcl2 transgene (upper and lower panels). Gates corresponding to Fr A-F in the BM and total (B220+CD19+), follicular (Fo, CD23+CD21+) and Marginal Zone (MZ, CD23-CD21hi) B cells in the spleen are highlighted. (d-e) Absolute numbers of B cells, gated as in (b-c), in Hardy Fractions in the BM (d) and in splenic subsets (e) from WT, P198A-Hom, WT BCL2 transgenic (BCL2) and P198A-Hom BCL2 transgenic (P198A-Hom BCL2) mice, here n=3 per group and representative of 4 independent experiments. Bars show means and 95% CI; statistical comparison was by two-way ANOVA with Bonferroni correction for multiple comparison, * =p<0.0001.

  7. Supplementary Figure 7 Normal TCR signaling and threshold for activation ZIP7-deficient thymocytes.

    (a-c) Mean phospho-specific antibody binding to indicated intracellular signaling molecules downstream of the TCR, 5 min after stimulation of WT (closed circles) and P198A-Hom (open circles) thymocytes with anti-CD3, gated on CD4+CD8+ (a), CD4+ (b) and CD8+ cells (c). (d-f) Mean phospho-specific antibody binding to indicated intracellular signaling molecules 30 min after treatment of WT (closed circles) and P198A-Hom (open circles) thymocytes with the PTEN specific inhibitor BpV(phen), in the absence of TCR stimulation, gated CD4+CD8+ (d), CD4+ (e) and CD8+ cells (f). In this figure, circles represent values from individual mice (n=3 mice per genotype), bars are means of groups and 95% CI. Data are representative of 3 independent experiments.

  8. Supplementary Figure 8 PTEN contributes to phosphatase activity, but PTEN haploinsufficiency does not rescue B cell development in ZIP7 deficiency; normal PLCγ2 kinase expression in P198A-Hom cells.

    (a) Reduced phosphatase activity in B cells from PTEN-deficient PTENffMb1Cre (n=2) mice compared with wild-type Mb1Cre controls (n=4). Plots show gating on the pre-B (Fraction D) population in these animals (left panel) and reduced phosphatase activity thereof in the absence of PTEN (middle panel, red fill: PTENffMb1Cre; blue fill: PTENwtMb1Cre); quantification in right panel. Bars show means and 95% CI; n=4 PTENwtMb1Cre and 2 PTENf/fMb1Cre mice; experiment done once. (b) Mean anti-PLCγ2 antibody staining in wild-type/P198A-heterozygote (closed circles) and P198A-Hom (open circles) SWHEL immature (B220+CD43-HEL+IgM+IgD-) B cells and B220-CD43- controls; bars show means and 95% CI (n=3 mice per group, experiment done once). (c-d) B cell numbers in irradiated CD45.1+ B6 mice reconstituted with WT (open triangles), PTENf/+Mb1Cre heterozygote (open circles), P198A-Hom (filled triangles) or P198A-Hom PTENf/+Mb1Cre compound mutant BM (filled circles), gated on Hardy Fractions A-F in the BM (c) and total B220+CD19+, follicular B220+CD19+CD23+CD21+ and marginal B220+CD19+CD23-CD21++ B cells in the spleen (d). Each symbol represents an individual mouse (n= 5 chimeric mice generated per genotype). Bars show means and 95% CI.

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Figures 1–8 and Supplementary Table 1

  2. Reporting Summary

About this article

Publication history